SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing significant volatility as investors react to the finalized Medicare Advantage rate increase for 2027, which arrived notably higher than initial market projections. While many in the community view this as a potential relief catalyst and a sign of sector stabilization, others remain cautious, debating the long-term impact of regulatory pressures and ongoing volatility across the managed care space.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is currently a focal point for the investment community as the company expands its strategic partnerships, specifically securing long-term agreements to supply custom artificial intelligence chips and infrastructure to industry giants like Google and Anthropic. While some investors are concerned about potential supply chain bottlenecks and short-term price volatility, others are debating the stock's fundamental valuation and viewing the recent dips as an opportunity to gain exposure to critical AI infrastructure.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant selling pressure after a major financial institution reiterated a bearish outlook, citing concerns over future growth, execution risks, and a valuation that many investors now see as disconnected from weakening fundamentals. Community sentiment is deeply polarized, with bears pointing to inventory headwinds and the upcoming SpaceX IPO as potential catalysts for further downside, while a vocal group of bulls remains optimistic, viewing the pullback as a buying opportunity based on their long-term conviction in the company's AI and robotics initiatives.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is seeing elevated bullish options activity and heightened community discourse as traders debate whether the stock is currently undergoing a technical accumulation phase or if ongoing manufacturing scaling challenges will continue to suppress price momentum. While speculative reports of a partnership with Meta-Bounds have fueled sentiment, investors remain focused on the company's ability to transition from pilot programs to high-volume commercial production.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is seeing significant volatility as investors digest finalized 2027 Medicare Advantage payment rates, which came in stronger than the initial government projections. The community is actively debating whether this relief rally provides a sustainable floor for the stock or if broader structural headwinds and regulatory pressures in the managed care sector will continue to weigh on long-term growth.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendys is attracting significant attention as investors speculate on potential buyout scenarios and aggressive international expansion, while heavy short interest continues to fuel intense debate regarding a possible short squeeze. The community is actively tracking the stock's relative strength and attractive dividend yield, often framing the current price levels as a prime accumulation opportunity ahead of anticipated leadership or acquisition news.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently experiencing intense volatility and downward pressure as the market reacts to a significant debt-related financing announcement and concerns over persistent high interest expenses. While the community is actively debating the stock's long-term sustainability due to its heavy debt load and potential for dilution, many traders are closely watching for a short squeeze setup, noting the stock's high institutional ownership and historical tendency for sudden, aggressive price swings.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is generating significant momentum as a legacy meme asset, with community members actively discussing its long-term cultural roots and potential as a disruptive force in the cryptocurrency space. Sentiment is divided between those treating it as a lighthearted, narrative-driven project and believers who argue its deep historical footprint distinguishes it from modern market cycles.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing renewed investor interest driven by a successful $600 million AAA-rated ABS transaction and the addition of new institutional partners, reinforcing confidence in its AI-driven credit underwriting model. The community is actively discussing the stock's oversold technical setup and its potential for a recovery as the company continues to onboard new partners despite broader macro-economic and geopolitical headwinds.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS Health is trending as market sentiment shifts following a relief rally for managed care stocks, driven by finalized CMS payment rates for Medicare Advantage that were more favorable than investors initially feared. The community is actively discussing the impact on earnings risk and the potential for a sector-wide re-rating, alongside ongoing debate regarding the company's long-term integration strategy and PBM business model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve

enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.

Medical device company enVVeno Medical Corporation (NVNO) on Wednesday announced that the U.S. Food &amp; Drug Administration (FDA) has refused to approve its application for its lead product, VenoValve, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).Following the announcement, NVNO shares plunged 71% by Wednesday afternoon, at the time of writing.Severe deep chronic venous insufficiency (CVI) is a long-term condition where the veins in the legs have difficulty returning blood to the heart, leading to blood pooling and various symptoms like swelling, aching, and skin changes. This occurs primarily due to damaged or weakened valves within the deep leg veins.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVNO">NVNO</a> rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while retail chatter rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:563/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_12_41_02_PM_png_bca2208bb7.webp" alt="NVNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="61"><figcaption>NVNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the company renegotiating with the FDA.<stembedurl>https://stocktwits.com/Flying_Trader2/message/625960642</stembedurl>Another user said that they see no value in the company with the VenoValve rejection.<stembedurl>https://stocktwits.com/kmx_swing/message/625941525</stembedurl>The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://envveno.com/envveno-receives-not-approvable-letter-from-the-fda-for-the-venovalve/">said</a> in a letter that it completed its review of the company’s application for VenoValve but has decided that it is unable to approve it in its current form. The agency said that data generated by the company for the application was not sufficient on its own to determine the favorability of the benefit-risk profile for VenoValve.The FDA also raised concerns about bias and the possibility that clinical improvement occurred as a result of the patients being enrolled in a study. The agency further raised safety concerns, which were attributed to the VenoValve open surgical procedure, and which required re-hospitalizations.CEO Robert Berman said that the company is disappointed by the FDA’s decision and highlighted that a high percentage of patients in a study showed significant clinical improvement after receiving VenoValve. Berman added that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of the device.The firm’s next steps may include a meeting with the FDA to discuss requirements for a potential resubmission of the VenoValve or appeal of the decision, along with appropriate next steps.NVNO stock is down by 59% this year and by about 77% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-says-tesla-model-yl-might-not-ever-come-to-us-markets/chsitLlRdhq">Elon Musk Said Tesla’s Model Y L Might Not Ever Come To US Markets – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It?

enVVeno Medical Corporation CEO Robert Berman said that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of its VenoValve device. 

Equity

This account has been verified as an official NVNO representative.

Verified Account

enVVeno Medical

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include VenoValve and enVVe. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

Current Price	$10.53
Prev Close	$10.53
Open	$10.30
Dividend Yield	0.00%
50-Day Moving Average	$10.63
Beta	1.45
Avg. Volume	16,171.54
PE Ratio	-0.32

52-Week High	$196.70
52-Week Low	$8.67
Market Capitalization	$6.9M
EPS (Annual)	-$33.06
Price to Book	0.25
Revenue Per Employee	$0.00

NVNO
enVVeno Medical Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVNO News

NVNOenVVeno Medical Corporation